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Abstract
Background: The absence of highly sensitive and specific serum biomarkers makes mass screening
for ovarian cancer impossible. The claudin proteins are frequently overexpressed in ovarian
cancers, but their potential as prognostic, diagnostic, or detection markers remains unclear. Here,
we have explored the possible use of these proteins as screening biomarkers for ovarian cancer
detection.
Methods: Claudin protein shedding from cells was examined by immunoblotting of conditioned
culture media. The presence of claudins in exosomes released from ovarian cancer cells was
demonstrated by sucrose gradient separation and immunogold electron microscopy experiments.
Claudin-4-containing exosomes in the plasma of ovarian cancer patients were evaluated in a pilot
panel of 63 ovarian cancer patients and 50 healthy volunteers. The CA125 marker was also
assessed in these samples and compared with claudin-4 positivity.
Results: We show that full-length claudins can be shed from ovarian cancer cells in culture and
found in the media as part of small lipid vesicles known as exosomes. Moreover, 32 of 63 plasma
samples from ovarian cancer patients exhibited the presence of claudin-4-containing exosomes. In
contrast, only one of 50 samples from individuals without cancer exhibited claudin-4-positive
exosomes. In our small panel, at a specificity of 98%, the claudin-4 and CA125 tests had sensitivities
of 51% and 71%, respectively. The two tests did not appear to be independent and were strongly
correlated.
Conclusion: Our work shows for the first time that claudin-4 can be released from ovarian cancer
cells and can be detected in the peripheral circulation of ovarian cancer patients. The development
of sensitive assays for the detection of claudin-4 in blood will be crucial in determining whether this
approach can be useful, alone or in combination with other screening methods, for the detection
of ovarian cancer.
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Background
Ovarian cancer is the fifth cause of cancer deaths in
women in the United States [1]. However, when detected
early, ovarian cancer has an excellent prognosis, with a 5-
year survival rate exceeding 90%. Unfortunately, because
of a lack of obvious symptoms and the current limitations
in detection techniques, only a small number of ovarian
cancers are detected early, while the vast majority (70%)
is diagnosed as advanced disease when the survival rate is
approximately 30% [1]. Among the problems related to
ovarian cancer detection is the lack of highly specific and
sensitive serum biomarkers. The most clinically useful
ovarian cancer biomarker, CA125, has been used to assess
response to treatment and monitor recurrence of CA125-
positive tumors [2], but unfortunately lacks both sensitiv-
ity and specificity required for the efficient detection of
ovarian cancer in the general population [3,4]. The sensi-
tivity of CA125 is limited by the fact that a significant pro-
portion of ovarian cancers do not express this marker,
especially tumors of clear cell, undifferentiated, and muci-
nous histological subtypes [5]. In addition, multiple gyne-
cological conditions can lead to elevated CA125 levels,
reducing its overall specificity [4,6]. A combination of
approaches involving serum CA125 detection and ultra-
sound imaging, while promising, still yielded positive
predictive values of approximately 20% for ovarian cancer
detection [7-9]. It has been suggested that combining
multiple serum markers may help achieve the sensitivity
and specificity required for the screening of ovarian cancer
[4,10]. There has therefore been a significant interest in
the identification and development of new ovarian cancer
markers.
Claudins are a family of transmembrane proteins crucial
in the formation and function of tight junctions, the most
apical contact between polarized cells [11]. Several clau-
din genes have been found aberrantly expressed in cancer
[12]. In particular, we and others have shown that clau-
din-3 and claudin-4 are elevated in ovarian cancer [13-
22]. The functional consequences of overexpressed clau-
din-3 and -4 in cancer remain unclear, but these proteins
may be important for invasion, motility, survival, and
metastasis [23-31]. In addition, certain claudins have
been suggested as prognostic markers in various cancers.
For example, in ovarian cancer, claudin-3 and claudin-7
expression has been shown to be inversely correlated with
survival [21,22]. Claudin-3 and claudin-4 expression was
shown to be associated with poor clinical outcome in
endometrial cancer [32] and renal cell carcinoma [33].
Exosomes are small (40–100 nm) membrane vesicles of
endocytic origins shed by multiple cell types, such as lym-
phocytes, dendritic cells, neurons, intestinal cells, and
others [34]. Interestingly, tumor cells have been shown to
release increased amounts of exosomes [35] and, in fact,
these vesicular structures were first observed in the periph-
eral circulation of women with ovarian cancer [36].
Although the exact mechanistic details of exosome forma-
tion remain unclear, the protein composition of exo-
somes reflects the cell of origin and may include both
cytoplasmic and membrane proteins. For example, exo-
somes from antigen-presenting cells contain MHC class I
molecules [37], and exosomes from enterocytes contain
intestinal enzymes [38]. It has therefore been hypothe-
sized that tumor-derived exosomes may contain specific
biomarkers for the detection of various cancers [39].
In this report, we show for the first time that intact claudin
proteins are released from ovarian cancer cells. The
released claudins are incorporated into exosomes and can
be detected in the media of cells expressing claudins, as
well as in the peripheral circulation of a majority of
women with ovarian cancer. Isolation of blood exosomes
followed by the detection of claudins may represent a
novel approach for the detection of ovarian cancer.
Methods
Cell Culture, Preparation of Cell Lysate and Culture Media
Ovarian cancer cell lines OVCAR-2, OVCAR-3, OVCA420,
OVCA433, BG-1, Hey, and UCI101 were cultured in
McCoy's 5A medium (Invitrogen Life Technologies,
Carlsbad, CA), supplemented with 10% fetal bovine
serum (FBS) and antibiotics (100 units/ml penicillin and
100 μg/ml streptomycin). The origin of these cell lines has
been documented [40]. Colon cancer cell lines HCT-116
and SW-480, and the breast cancer cell line MCF-7 were
also cultured in McCoy's 5A medium. Ovarian cancer cell
line A2780 was maintained in RPMI-1640 medium sup-
plemented with 10% FBS, antibiotics (100 units/ml peni-
cillin and 100 μg/ml streptomycin), and 4 μg/ml bovine
insulin (Invitrogen Life Technologies).
Whole cell lysates were prepared by adding lysis buffer
(62.5 mM Tris-HCl (pH 6.8), 10% glycerol, 2% SDS) to
80% confluent cell cultures. Protein concentration was
determined using the BCA assay kit (Pierce, Rockford, IL).
For the preparation of the conditioned culture media,
cells were grown to 80% confluency and then with FBS-
free media for 24 hours. The conditioned culture media
were collected and centrifuged at 1,000 rpm for 10 min to
remove cells and debris, and were further concentrated by
Centriplus YM-10 (Millipore) prior to immunoblotting.
Immunoblotting
Fifteen μg of lysate proteins or 10 μl of concentrated cul-
ture media were separated by 10–20% SDS-PAGE (Tris-
Glycine gels, Invitrogen Life Technologies, Carlsbad, CA),
and transferred to PVDF membranes (Millipore, Bedford,
MA). The membranes were blocked with 5% nonfat dry
milk, washed in Tris-Buffered Saline with 0.1% Tween 20BMC Cancer 2009, 9:244 http://www.biomedcentral.com/1471-2407/9/244
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buffer and probed with primary antibodies against clau-
din-1 (1:200 dilution), claudin-3 (1:200 dilution), clau-
din-4 (1:400 dilution), or claudin-5 (1:200 dilution). All
the primary antibodies were obtained from Invitrogen.
After washing in TBST, membranes were incubated with
HRP-conjugated secondary antibody (anti-rabbit or anti-
mouse IgG: 1:10,000; Amersham Biosciences Corp, Pis-
cataway, NJ). For detection, enhanced chemiluminesence
was carried out using the ECL plus kit (Amersham Bio-
sciences Corp). Rabbit anti-claudin-4 antibody (Abcam
Inc., Cambridge, MA) was used at a 1:200 dilution for the
detection of claudin-4 from plasma exosomes.
Exosome Preparation from Culture Media
BG-1 cells were cultured to 80–90% confluency and then
incubated FBS-free media for 24 hours to allow accumu-
lation of exosomes. The conditioned culture media were
harvested and subjected to two centrifugations (2,000 g
and 10,000 g) to remove cells and debris. Exosomes were
then pelleted from the media at 100,000 g for 2 hour
using a SW41Ti rotor, washed once in cold PBS, and resus-
pended in 50 μl of PBS.
Sucrose Gradient
Fresh exosomes obtained by ultracentrifugation were
resuspended in 2 ml of 2.5 M sucrose, 20 mM Tris-HCl
(pH 7.4), loaded at the bottom of a 8 ml linear sucrose
gradient (2.0 – 0.25 M sucrose, 20 mM Tris-HCl (pH 7.4))
in a SW41 Ti tube, and centrifuged at 270,000 g for 16
hour at 4°C. Gradient fractions (1 ml) were collected
from the bottom of the tube and the presence of claudins
in the various fractions was assessed by immunoblotting
as described above. The density of each fraction was
assessed by measuring the weight of 500 μl aliquots.
Transmission Electron Microcopy (TEM)
Exosomes isolated from BG-1 culture media were
adsorbed to glow discharged 400 mesh carbon-coated
parlodion copper grids (Pella) for 2 min, and briefly
rinsed in 1× filtered PBS (Gibco). Exosomes on grids were
then fixed in 1% glutaraldehyde and negatively stained
with 1% phosphotungstic acid, before TEM. For immuno-
gold electron microscopy, the exosomes on the grids were
blocked in filtered 1% BSA for 10 min and the grids
floated in the primary antibody solution (1:2 dilution of
claudin-4 in blocking solution) in a humidity chamber for
2 hours at room temperature. The primary antibody was
omitted from grids used as negative controls. After pri-
mary antibody incubation, grids were washed in blocking
solution for 10 min, briefly rinsed in PBS, and incubated
with the secondary 6-nm gold-conjugated goat anti-rabbit
antibody (Jackson Immunochemical; diluted 1:40 in PBS)
for 1 hour in a humidity box. The samples were then
placed on PBS for 10 min., fixed in 2% glutaraldehyde for
5 min, rinsed again in PBS, and then deionized water.
Finally the grids were floated on 2 consecutive drops of fil-
tered aqueous 2% Uranyl Acetate for 1 min each (Pella)
and blot dried with Whatman # 1 filter paper. Both nega-
tively stained and immunogold labeled grids were viewed
on a Hitachi H-7600 TEM operating at 80 kV and images
were captured with a 1 K × 1 K CCD by AMT.
Pulse-Chase Experiments and Immunoprecipitation
BG-1 cells were cultured to 80–90% confluency, incu-
bated for 1 hour with methionine- and cysteine-free
DMEM medium (Invitrogen) and then labeled for 20 min
with 100 μCi/ml L-[35S]methionine and L-[35S]cysteine
using the Protein Labeling Mix (PerkinElmer NEG072).
After labeling, the cells were incubated with complete
McCoy's 5A medium for 40 min to allow [35S] incorpora-
tion into proteins. After chasing in serum-free McCoy's 5A
medium for 0, 2, 6, or 24 hours, the culture media were
centrifuged at 2,000 g for 10 min, followed by 10,000 g
for 20 min at 4°C, concentrated to 500 μl, and mixed with
2× immunoprecipitation (IP) buffer and protease inhibi-
tor cocktail (Sigma) before IP. In order to assess total
incorporation, a cell lysate was prepared immediately
after labeling using cold IP buffer (50 mM Tris-Cl (pH
7.4), 150 mM NaCl, 1 mM EDTA, and 1% NP-40) con-
taining protease inhibitor cocktail. The lysate was cleared
by centrifugation at 10,000 g for 20 min at 4°C.
For immunoprecipitation, both culture media and cell
lysates were incubated overnight with 10 μg claudin-4
antibody (Invitrogen) and 50 μl protein A-Sepharose
beads (Amersham Biosciences) at 4°C. After washing the
beads three times with IP buffer, immune complexes were
boiled for 5 min in 2× sample buffer and analyzed by
SDS-PAGE. Radiolabeled bands were quantitated using a
phosphorimager.
Plasma Samples and CA125 detection
Plasma was obtained from whole blood samples received
from women prior to surgery for ovarian cancer at Johns
Hopkins School of Medicine, as well as healthy volunteers
with informed consent. All the patients used for this study
were diagnosed with high-grade serous ovarian cancer.
The details of the cancer diagnosis are included in Table 1.
For both cancer patients and healthy volunteers, plasma
CA125 levels were determined by an ELISA kit from Pan-
omics Inc. according to the manufacturer's instructions.
Isolation of circulating exosomes
Control and patient plasma (200 μl) were diluted to 1 ml
with RPMI-1640 medium (Invitrogen), centrifuged at
2,000 g for 10 min at 4°C, the supernatants were then
transferred to 15 ml tubes (avoiding pellet at the bottom
or fat at the top if present) and further diluted to 10 ml
with cold PBS, and centrifuged at 10,000 g for 20 min at
4°C to remove large debris. The samples were then trans-
ferred to ultracentrifuge tubes and exosomes were pelleted
at 100,000 g for 2 hour using SW41Ti rotor. FollowingBMC Cancer 2009, 9:244 http://www.biomedcentral.com/1471-2407/9/244
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centrifugation, exosomes were resuspended in 50 μl PBS.
Ten μl of exosomes were used for immunoblotting and
Abcam anti-claudin-4 antibody was used to detect clau-
din-4 from plasma exosomes.
Statistics
The relationship between claudin-4 and CA125 positivity
was evaluated using Fisher's Exact test.
Results
Cancer cells in culture release claudin proteins
In order to test the possibility that claudin proteins may
be released from cells, we looked for the presence of clau-
dins in conditioned culture media from ovarian cancer
cell lines. Culture media from cell lines OVCAR-2,
OVCAR-3, OVCA420, OVCA433, BG-1, Hey, UCI101,
and A2780 were collected and immunoblotting was per-
formed to detect claudin-1, claudin-3, claudin-4, and
claudin-5 in the conditioned media (Figure 1A). Interest-
ingly, the full-length claudins were detected in the media
of several ovarian cancer cell lines. The presence of clau-
dins in the media corresponded to expression of these
claudins in the various cell lines and claudin proteins
were not detected in the media of cell lines lacking their
expression. The correlation between expression in the
lysates and presence in the media was striking, with the
exception of claudin-3 in HEY cells, where expression of
the protein was very low in the lysate, but claudin-3 was
nonetheless detectable in the media.
Because the expression of claudins have been detected in
other cancers [12], we next sought to determine whether
these proteins might also be secreted by other cancer cell
lines. Two colon cancer lines (SW-480 and HCT-116) and
one breast cancer cell line (MCF-7) were examined for the
release of claudins. Again, we found that these cell lines
shed claudin proteins in the media at levels roughly pro-
portional to their expression patterns (Figure 1B). Overall,
our findings show that, when expressed in a cell, a fraction
of the claudin proteins can be released in the media.
The released claudin proteins are incorporated into 
exosomes
To determine whether claudins are released in the media
as free molecules or as part of larger complexes, we
Table 1: Cancer patient information, CA125 values, and claudin-
4 positivity.
Sample Stage CA125 (unit/ml) Claudin-4*
P5 4 11576 2
P41 3 641 2
P4 4 387 2
P36 4 5255 2
P34 3 213 2
P32 4 950 2
P3 4 3225 2
P29 4 6084 2
P26 4 1995 2
P25 4 9937 2
P24 3 965 2
P23 3 147 2
P21 3 2169 2
P10 3 10601 2
P54 4 164 2
P56 4 96 2
P57 4 826 2
P59 4 1251 2
P63 3 3707 2
P72 3 1110 2
P78 3 1773 2
P79 3 1805 2
P82 3 456 2
P39 3 599 1
P37 3 411 1
P22 3 963 1
P52 4 1447 1
P53 4 911 1
P60 4 590 1
P67 3 726 1
P75 3 1632 1
P80 3 349 1
P9 4 95 0
P8 3 85 0
P7 4 184 0
P6 4 45 0
P40 4 55 0
P38 3 5921 0
P31 3 29 0
P30 3 451 0
P2 4 208 0
P19 4 0 0
P14 3 221 0
P1 4 0 0
P51 4 1407 0
P55 4 502 0
P58 4 744 0
P61 3 380 0
P62 3 3775 0
P64 3 120 0
P65 3 232 0
P66 3 11 0
P68 3 3890 0
P69 3 600 0
P70 3 54 0
P71 3 83 0
P73 3 115 0
P74 3 38 0
P76 3 50 0
P77 3 0 0
P81 3 101 0
P83 3 194 0
P84 3 73 0
*scoring of claudin-4 intensity was performed as follows: 2, strong 
band; 1, weak to moderate band; 0, undetectable.
Table 1: Cancer patient information, CA125 values, and claudin-
4 positivity. (Continued)BMC Cancer 2009, 9:244 http://www.biomedcentral.com/1471-2407/9/244
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focused on claudin-4 and performed a series of sedimen-
tation experiments using media from the BG-1 ovarian
cancer cell line. BG-1 cells were chosen as a model for
these experiments as they shed relatively high levels of
claudin-4. Low speed centrifugation (10,000 g) removed
cells and cell debris from the media, but did not signifi-
cantly affect the amount of claudin-4 in the supernatant
(Figure 2A). In contrast, high speed ultracentrifugation
(100,000 g) of the media significantly reduced the
amount of claudin-4 detectable in this fraction and trans-
ferred this protein to the pellet. These results suggested
that a significant portion of the released claudin was part
of a relatively large complex that could be sedimented at
100,000 g. Because claudins are membrane proteins, we
considered the possibility that they may be released
within lipid vesicles known as exosomes. To test this
hypothesis, the pellet from the BG-1 media was resus-
pended in PBS and subjected to a sucrose gradient separa-
tion. Fractions of increasing densities were collected and
assayed by immunoblotting for the presence of claudin-4.
The bulk of the claudin signal was identified in fractions
of densities of 1.15–1.21 g/ml (Figure 2B), corresponding
to the reported densities of exosomes [34,41].
In order to further demonstrate that the released claudin
proteins were contained within exosomes, electron micro-
scopy experiments were performed. When examined by
TEM using negative staining, the pellet from BG-1 media
contained a large number of cup-shaped vesicles of
approximately 40–100 nm in diameter (Figure 2C), con-
sistent with the reported morphology and size of exo-
somes [34]. Immunogold electron microscopy
experiments with an anti-claudin-4 antibody confirmed
the presence of claudin-4 within the exosomes (Figure
Claudin proteins are shed from cancer cell lines Figure 1
Claudin proteins are shed from cancer cell lines. A, Cell lysates and culture media were collected from ovarian cancer 
cell lines, and analyzed by immunoblotting for the expression of claudin-1, claudin-3, claudin-4 and claudin-5. Ovarian cancer 
cell lines used: OVCAR-2 (1), OVCAR-3 (2), OVCA420 (3), OVCA433 (4), BG-1 (5), Hey (6), UCI101 (7), and A2780 (8). B, 
Cell lysates and culture media were collected from various cancer cell lines, and analyzed by immunoblotting for the expres-
sion of claudin-1, claudin-3, claudin-4 and claudin-5. Cell lines analyzed are: colon cancer HCT-116 (1), colon cancer SW-480 
(2), breast cancer MCF-7 (3), and ovarian cancer OVCAR-3 (4). Claudins expressed in the various cell lines were released in 
the media.
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2D). Negative controls lacking primary antibody did not
exhibit the presence of labeled exosomes (data not
shown).
To gain a better understanding of the kinetics of release of
claudin-containing exosomes by ovarian cells, BG-1 cells
were pulse-labeled with [35S]methionine/[35S]cysteine
and the media was collected at different times before
immunoprecipitation with a claudin-4 antibody. In order
to evaluate the total amount of labeled protein, a cell
lysate was also produced immediately following [35S]-
labeling and immunoprecipitated with the anti-claudin-4
antibody. Labeled claudin-4 was present in the media as
early as 2 hours post-labeling (Figure 3A) and reached a
level of approximately 3–4% of the total labeled claudin-
4 after 24 hours. The kinetics of release of claudin-4 in the
media were linear (Figure 3B), suggesting that the labeled
claudin-4 protein was relatively stable during this time-
frame.
Claudin-4 can be found in blood exosomes from ovarian 
cancer patients, but not in healthy controls
Our finding that claudins can be released from ovarian
cancer cells suggests that these proteins may become use-
ful for the detection of ovarian cancer in patients. We first
sought to determine whether exosome-associated clau-
dins could indeed be detected in the peripheral circula-
tion of ovarian cancer patients. Plasma samples from 63
high-grade serous ovarian cancer patients treated at Johns
Hopkins University, as well as 50 healthy volunteers were
assessed. Exosomes were purified from the plasma by
ultracentrifugation and assayed for the presence of clau-
Released claudin proteins are present in exosome particles Figure 2
Released claudin proteins are present in exosome particles. A, BG-1 culture media was centrifuged sequentially and 
analyzed by immunoblotting for the expression of claudin-4. Claudin-4 was sedimented by a 100,000 g centrifugation (100 K 
Centrif.) but not by 10,000 g centrifugation (10 K Centrif.). B, Sucrose gradient analysis of the 100,000 g pellet. Following sepa-
ration of the pellet on a sucrose gradient, ten successive fractions of increasing densities were collected and analyzed by immu-
noblotting for the expression of the indicated claudin proteins. The density of the various fractions was measured and is 
indicated on top of the lanes. C, Transmission electron microscopy image of exosomes released from ovarian cancer cells. Exo-
somes isolated from BG-1 culture media by the 100,000 g centrifugation were fixed, negatively stained, and observed by TEM. 
The exosomes observed are 40–100 nm in diameter and exhibit the typical cup-shaped morphology. D, Indirect immunogold 
labeling with anti-claudin-4 antibody followed by a secondary antibody coupled to 6-nm gold particles. The gold particles (dark 
dots on the figure) clearly localize to the exosomes.
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din-4 and claudin-3 by immunoblotting. Several plasma
samples from patients with ovarian cancer exhibited high
levels of claudin-4, while blood from control individuals
showed very low or undetectable levels (Figure 4A). The
pattern obtained with claudin-3 was somewhat similar,
but the background levels in the plasma of unaffected
women were much higher (data not shown). Claudin-3
was therefore considered less likely than claudin-4 to rep-
resent a useful plasma-based ovarian cancer biomarker
and was not studied further. Among the 63 ovarian cancer
patients, 23 samples demonstrated a strong claudin-4
band with 9 additional samples exhibiting low to moder-
ate levels (Table 1). Thirty one samples had no detectable
claudin-4 protein. In contrast, among the control group
(n = 50), only one sample was positive (at a low level) and
all the other plasma samples were negative (Table 2).
Based on these figures, claudin-4 has a sensitivity of 51%
(32/63) and specificity of 98% (49/50) for the detection
of ovarian cancer.
Comparison of claudin-4 and CA125 levels
CA125 is the most clinically useful ovarian cancer biomar-
ker. We therefore wished to compare the claudin-4 posi-
tivity with CA125 values in our tumor panel. Tables 1 and
2 show claudin-4 and CA125 values for cancer patients
and healthy controls, respectively. Cancer patients that
demonstrated high levels of CA125 also tended to exhibit
high levels of claudin-4 (Figure 4B). With a CA125 thresh-
old of 125 U/ml, chosen to obtain a specificity of 98%, the
CA125 sensitivity was approximately 71% (45/63). At
that threshold, several of the claudin-4-negative plasma
The kinetics of claudin release Figure 3
The kinetics of claudin release. A, BG-1 cells were 
pulsed-labeled with [35S]methionine and [35S]cysteine, chased 
for various times as indicated, before the media was col-
lected. Claudin-4 was immunoprecipited from the media or 
from the [35S]-labeled whole cell lysate (as control for the 
total amount of labeled claudin-4) and analyzed by SDS-
PAGE. Claudin-4 is released rapidly in the media, with radi-
olabeled claudin-4 detectable as early as 2 hours post-labe-
ling. B, The radiolabeled claudin-4 released into the culture 
media was quantitated by phosphorimaging of the blot shown 
in (A) and plotted against time. Claudin-4 increase in the 
media is linear with time.
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samples were in the CA125-positive range, including
some samples with very high CA125 (such as P38, P62,
and P68). 31 of the 32 cancer patients identified as posi-
tive by claudin-4 were also positive using the CA125
marker and 17 patients were negative for both (Table 3).
Using Fisher's exact test, the association between claudin-
4 and CA125 positivity was shown to be highly significant
(P = 3.4 × 10-6), confirming the lack of independence
between these two markers. The false positive obtained
with CA125 (N59) was different than the one obtained by
claudin-4 (N32) (Table 2).
Discussion
Because of the significant difference between the survival
rates of patients with early and advanced ovarian cancer,
there has been a sustained interest in the identification of
blood markers that may help detect ovarian cancer at an
early stage. However, because of a relatively low specificity
and sensitivity, the CA125 assay is currently not deemed
appropriate for the screening of the general population
[4]. Importantly, it has been shown that combining
CA125 with other markers can improve the predictive
value, leading to speculation that the development of a
useful test may be possible, provided the right combina-
tion of markers [4,10]. In this context, there has been a
considerable effort in trying to identify novel circulating
biomarkers for ovarian cancer. Several ovarian biomark-
ers, such as Kallikreins, osteopontin, leptin, HE-4, LPA,
MUC1 and SLPI, [3,10,18,42-45] have been identified in
the past several years through various approaches, includ-
ing gene expression profiling and proteomics analysis of
ovarian tumors. The usefulness of these markers alone or
in various combinations still remains to be determined,
although initial studies using with multi-marker combi-
nations are promising [10].
Claudin-3 and -4 have emerged as proteins commonly
elevated in ovarian cancer [13-22], but because they are
integral membrane proteins, they had not previously been
suggested as serum markers. Here, we demonstrate that
full length claudins can be shed into the media of ovarian
cancer cell lines (Figure 1). Consistent with the fact that
these proteins are transmembrane proteins, we found the
claudins to be present in small membrane vesicles known
as exosomes, rather than soluble entities in the media
(Figures 2 and 3). This conclusion was drawn from several
lines of evidence. First, we showed that a significant por-
tion of the claudin signal was found in the pellet follow-
ing high speed ultracentrifugation, suggesting that these
proteins are indeed part of large complexes. Second, using
density gradient analysis, we demonstrated that the clau-
din complexes exhibited a density range consistent with
Table 2: CA125 levels and claudin-4 positivity in the cancer-free 
controls
Sample CA125 (unit/ml) Claudin-4*
N32 0 1
N2 0 0
N3 41 0
N4 4 0
N5 122 0
N6 44 0
N7 0 0
N8 0 0
N9 0 0
N21 0 0
N22 8 0
N23 0 0
N24 0 0
N25 76 0
N26 27 0
N27 6 0
N28 4 0
N29 0 0
N30 0 0
N31 20 0
N33 1 0
N34 0 0
N35 0 0
N36 47 0
N37 0 0
N38 0 0
N39 0 0
N19 9 0
N15 0 0
N11 0 0
N1 0 0
N10 30 0
N41 0 0
N42 0 0
N43 0 0
N44 22 0
N45 80 0
N46 0 0
N47 16 0
N48 99 0
N49 27 0
N51 0 0
N52 0 0
N53 85 0
N54 0 0
N55 9 0
N56 4 0
N57 0 0
N58 2 0
N59 171 0
*scoring of claudin-4 intensity was performed as follows: 2, strong 
band; 1, weak to moderate band; 0, undetectable.
Table 3: CA125 and Claudin-4 immunopositivity in ovarian 
cancer plasma samples
Cl4 + Cl4 -
CA125 Positive 31 14
CA125 Negative 1 17BMC Cancer 2009, 9:244 http://www.biomedcentral.com/1471-2407/9/244
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the density of exosomes. Finally, electron microscopy
experiments clearly showed the presence of cup-shaped
40–100 nm vesicles in our preparations, and immuno-
gold electron microscopy clearly localized claudin-4 to
these exosomes (Figure 2C,D). In an attempt to clarify the
kinetics of claudin shedding in ovarian cells, we per-
formed a pulse-chase experiment and showed that clau-
dins were released relatively rapidly from the cells
following protein synthesis (a claudin band was detecta-
ble as early as 2 hours post-labeling) and that the kinetics
of release were linear, even 24 hr post-labeling (Figure 3).
These results further confirmed the release of newly syn-
thesized claudin in the media, and the linearity suggested
that the released claudin-4 is stable in the media.
Because tumors are known to produce exosomes and
release them in the bloodstream, our findings suggested
that plasma from ovarian cancer patients may exhibit ele-
vated levels of claudin-containing exosomes. The analysis
of a pilot panel of ovarian cancer cases (63 cancer patients
and 50 controls) did indeed show that several ovarian
cancer patients exhibited extremely high levels of claudin-
4 in the plasma, while control individuals did not typi-
cally show elevated amounts of this protein (Figure 4).
The current results therefore suggest that there is potential
for claudins to become useful ovarian cancer detection
markers either alone or in combination with other mark-
ers/strategies.
While the current work establishes that claudins can
indeed be present in the peripheral circulation of ovarian
cancer patients, several important issues will need to be
clarified in subsequent studies before claudin-4 can be
considered a viable biomarker for ovarian cancer detec-
tion. As currently performed (immunoblotting), the clau-
din-4 test has a lower sensitivity than CA125 (51% vs 71%
at a specificity of 98%) and there was significant overlap
between CA125 and claudin-4 positivity in our pilot
study. In fact, of the 32 positive samples identified by the
claudin-4 test, 31 were also CA125 positive and 17 sam-
ples (27%) were negative by both the CA125 and claudin-
4 assays. Nonetheless, an improvement in the detection
strategy (including the development of an ELISA-based
test) may significantly increase the sensitivity of the clau-
din-4 test. Moreover, since the patients included in this
study were restricted to those with late stages, high grade
serous ovarian cancers, further studies with a larger cohort
will be necessary to clearly assess the potential of claudin-
4 in other subtypes, in low grades, and in early stages
patients. Significantly, unlike CA125, claudin-4 and clau-
din-3 have been shown elevated in all subtypes of ovarian
cancer [14]. In addition, we have identified a stage I
patient that is negative for CA125, but exhibit claudin-4
positivity (data not shown), suggesting that it is possible
for early CA125-negative cases to be claudin-4 positive.
Because of the known limitations of CA125 for the detec-
tion of early ovarian cancer, the finding that claudin-4 can
possibly detect early cases of ovarian cases is particularly
intriguing. A follow up study with a more sensitive detec-
tion strategy and a larger number of ovarian cancer
patients (with tumors of various stages and grades) tested
for circulating claudin-4 will help to clarify these issues.
The current work shows that a small proportion of unaf-
fected individuals may be recorded as positive (1 out of
50), but a more accurate determination will have to be
performed and its association with CA125 levels assessed.
Circulating tumor-derived exosomes have previously
been found in cancer patients [36,46,47] and the detec-
tion of blood exosomes has therefore been suggested as a
strategy for the detection of cancer [39,46]. However, to
fully exploit a detection assay based on exosomes, it is cru-
cial to distinguish tumor-derived exosomes from those
derived from normal cells. It has been shown that the
ovarian cancer proteins CD24 and EpCAM can indeed be
found in exosomes from ascites fluid of ovarian cancer
patients [47]. In addition, circulating exosomes from
ovarian cancer patients were shown to contain a specific
set of microRNAs corresponding to the expression profiles
identified in the tumors from the corresponding patients
[46]. The data presented here show that ovarian cancer-
derived exosomes contain high levels of the membrane
protein claudin-4. While claudins were not detectable
directly from plasma, the enrichment of exosomes from
the plasma (through ultracentrifugation) allowed us to
detect these proteins with great sensitivity. This finding,
together with the reports of other ovarian markers in exo-
somes [46,47], suggests that exosomes may contain sev-
eral proteins that may also be useful as markers, and the
ease of exosomes enrichment provides an elegant
approach for the purification of these proteins from other
plasma components. Exosomes derived from different
cancers will likely have a different protein composition
[48], suggesting a possibility to identify a cancer based on
the composition of the detected exosomes. For example,
following the isolation of plasma exosomes from a
patient, the analysis of the exosome composition may
help determine whether the exosomes are derived from
normal or tumor cells. The detection of abnormal exo-
somes would suggest the presence of a tumor in the
patient and the exact composition of these exosomes may
then allow the identification of the site of origin of the
tumor.
Conclusion
Much work remains to be done to clearly demonstrate a
clinical use for claudins and exosomes in the detection of
ovarian cancer. In particular, the development of a high-
throughput approach for the detection of circulating clau-
din-4 will be crucial, as our current approach involvingBMC Cancer 2009, 9:244 http://www.biomedcentral.com/1471-2407/9/244
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exosomes purification and detection by immunoblotting
does not allow for large scale population testing and does
not appears to provide improved sensitivity over the cur-
rently used CA125 marker. However, our work shows for
the first time that claudins may indeed become useful as
ovarian cancer detection biomarkers because of their
incorporation into exosomes shed by ovarian cancer cells.
Whether the information provided by a blood-based clau-
din-4 test will be complementary to CA125 or merely
redundant remains to be fully assessed. In any case,
because there is evidence that most cancer cells release
exosomes, the use of exosomes-associated biomarkers
represents an exciting new possibility for the detection of
a variety of cancers.
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